Larvol Delta - Asher-Bio-Announces-Dosing-of-First-Patient-in-Phase-1a1b-Clinical-Trial-of-AB248-a-Cistargeted-IL2-Immunotherapy-Product-Candidate-for-the-Treatment-of-Locally-Advanced-or-Metastatic-Solid-Tumors

AB248 - Asher Biotherap

Keytruda (pembrolizumab) - Merck (MSD)

https://www.businesswire.com/news/home/20230117005288/en/Asher-Bio-Announces-Dosing-of-First-Patient-in-Phase-1a1b-Clinical-Trial-of-AB248-a-Cis-targeted-IL-2-Immunotherapy-Product-Candidate-for-the-Treatment-of-Locally-Advanced-or-Metastatic-Solid-Tumors

Jan 17, 2023

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next